Evidence map›Paper›PMID 36889543›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2023

Schwann Cell Remyelination in the Multiple Sclerosis Central Nervous System.

Laura Ghezzi, Bryan Bollman, Luca De Feo, Laura Piccio, Bruce D Trapp, Robert E Schmidt, Anne H Cross

Open access · bronzeAbstract read
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Laura GhezziDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri. Electronic address: lghezzi@wustl.edu.
Bryan BollmanDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri.
Luca De FeoDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri.
Laura PiccioDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri; Brain and Mind Centre and Charles Perkins Centre, School of Medical Sciences, Neuroscience, University of Sydney, Sydney, New South Wales, Australia.
Bruce D TrappDepartment of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Robert E SchmidtDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.
Anne H CrossDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri.
Washington University in St. Louis · USCleveland Clinic Lerner College of Medicine · USThe University of Sydney · AU

Funding

Pathogenesis of Neurological Disability in Primary Diseases of MyelinR35NS097303 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI TRAPP, BRUCE D · 2017 to 2024
$6.9M
NINDS NIH HHS R35 NS097303
6 · The paper itself

Abstract

Multiple sclerosis (MS) is a central nervous system (CNS) demyelinating disease. Failure to remyelinate successfully is common in MS lesions, often with consequent neuronal/axonal damage. CNS myelin is normally produced by oligodendroglial cells. Remyelination by Schwann cells (SchC) has been reported in spinal cord demyelination, in which SchCs are in close proximity to CNS myelin. We identified an MS cerebral lesion that was remyelinated by SchCs. This prompted us to query the extent of SchC remyelination in the brain and spinal cords of additional autopsied MS specimens. CNS tissues were obtained from the autopsies of 14 MS cases. Remyelinated lesions were identified by Luxol fast blue-periodic-acid Schiff and solochrome cyanine staining. Deparaffinized sections containing remyelinated lesions were stained with anti-glial fibrillary acid protein to identify reactive astrocytes. Glycoprotein P zero (P0) is a protein exclusive to peripheral but not CNS myelin. Areas of SchC remyelination were identified by staining with anti-P0. Myelinated regions in the index case cerebral lesion were confirmed to be of SchC origin using anti-P0 staining. Subsequently, 64 MS lesions from 14 autopsied MS cases were examined, and 23 lesions in 6 cases showed remyelination by SchCs. Lesions from the cerebrum, brainstem, and spinal cord were examined in each case. When present, SchC remyelination was most commonly located adjacent to the venules and associated with a lower surrounding density of glial fibrillary acid protein

Indexed as

Multiple SclerosisRemyelinationCentral Nervous SystemGlial Fibrillary Acidic ProteinHumansMyelin SheathSchwann CellsSpinal CordGlial Fibrillary Acidic Proteindemyelinationmultiple sclerosisoligodendrocytesremyelinationSchwann cells

Identifiers

PMID36889543
PMCPMC10330052
OpenAlexW4323321919

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.